The future of cancer cell detection is promising, with ongoing research focused on developing more precise, non-invasive, and cost-effective methods. Liquid biopsies, which analyze circulating tumor DNA (ctDNA) in the blood, are being explored as a less invasive alternative to traditional biopsies. Additionally, the integration of big data analytics and personalized medicine approaches are expected to revolutionize the way cancer is detected and treated, allowing for tailored interventions based on an individual's unique genetic profile.
